Exane Derivatives’s Aphria Inc. Common Shares APHA Stock Holding History

Exane Derivatives’s Portfolio APHA Stock Details APHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,927	Closed	-$53.8K	–	1095
2021 Q1	$53.8K	Sell	2,927 -814	-22%	-$13.2K	0.02%	509
2020 Q4	$25.9K	Sell	3,741 -740	-17%	-$4.62K	0.01%	501
2020 Q3	$19.9K	Hold	4,481	–	–	0.01%	443
2020 Q2	$19.2K	Sell	4,481 -23,000	-84%	-$88.2K	0.01%	399
2020 Q1	$84.1K	Buy	27,481 +10,846	+65%	+$43.3K	0.02%	302
2019 Q4	$87.1K	Sell	16,635 -44,715	-73%	-$220K	0.02%	332
2019 Q3	$318K	Sell	61,350 -41,780	-41%	-$265K	0.06%	195
2019 Q2	$723K	Buy	103,130 +79,350	+334%	+$600K	0.13%	134
2019 Q1	$222K	Buy	+23,780	New	+$209K	0.04%	211

Exane Derivatives's APHA Position: Q2 2021 in Review

Exane Derivatives sold out of Aphria Inc. Common Shares (APHA) in Q2 2021, closing a stake of 2,927 shares — an estimated $53.8K sold.

Exane Derivatives first reported a position in APHA in Q1 2019 and held it in 9 quarters. The position peaked at $723K in Q2 2019. 0 funds tracked by Wall St. Rank hold APHA as of Q2 2021.

Exane Derivatives reported no remaining Aphria Inc. Common Shares position as of Q2 2021 after selling out during the quarter.
Exane Derivatives sold 2,927 Aphria Inc. Common Shares shares in Q2 2021, an estimated $53.8K.
Exane Derivatives first reported a position in Aphria Inc. Common Shares in Q1 2019 and held it in 9 quarters.
Exane Derivatives's Aphria Inc. Common Shares position peaked at $723K in Q2 2019.
0 funds tracked by Wall St. Rank held Aphria Inc. Common Shares as of Q2 2021.

Based on Exane Derivatives's 13F filing for Q2 2021, filed 28 Jul 2021.